These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32947075)

  • 1. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
    Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
    Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
    J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud D; Vermeire S; Verstockt B
    Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Therapeutics for Inflammatory Bowel Disease.
    Dulai PS; Sandborn WJ
    Curr Gastroenterol Rep; 2016 Sep; 18(9):51. PubMed ID: 27461274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
    Restellini S; Khanna R; Afif W
    Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary.
    Mountifield R
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():25-26. PubMed ID: 33817852
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    Dutt K; Vasudevan A
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
    Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.
    Hemperly A; Sandborn WJ; Vande Casteele N
    Inflamm Bowel Dis; 2018 Nov; 24(12):2527-2542. PubMed ID: 29788338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
    Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
    Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD.
    Abreu MT
    Dig Dis Sci; 2019 Dec; 64(12):3377-3381. PubMed ID: 31628571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.